loading page

Rituximab ameliorated PR3-ANCA positive vasculitis with rheumatoid arthritis simultaneously
  • Akihiro Yamada,
  • Ayuko Sogabe,
  • Yasuaki Okuda
Akihiro Yamada
Dohgo Spa Hospital

Corresponding Author:[email protected]

Author Profile
Ayuko Sogabe
Dohgo Spa Hospital
Author Profile
Yasuaki Okuda
Dohgo Spa Hospital
Author Profile


We treated PR3-ANCA positive vasculitis patient with bilateral ischemic peroneal nerve paralysis accompanying rheumatoid arthritis. Pathology showed mild vasculitis. With PR3-ANCA amelioration, the level of complement 3, anti-CCP and neurological disability normalized simultaneously responding to rituximab. This result means the shared pathogenic pathway of PR3-ANCA vasculitis and rheumatoid arthritis.
16 Apr 2020Submitted to Clinical Case Reports
01 May 2020Submission Checks Completed
01 May 2020Assigned to Editor
18 May 2020Reviewer(s) Assigned
02 Jun 2020Review(s) Completed, Editorial Evaluation Pending
05 Jun 2020Editorial Decision: Revise Minor
27 Jul 20201st Revision Received
28 Jul 2020Submission Checks Completed
28 Jul 2020Assigned to Editor
28 Jul 2020Review(s) Completed, Editorial Evaluation Pending
03 Aug 2020Editorial Decision: Accept